Vioxx Cardiovascular Safety Questioned In Original NDA, Review Docs Show
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The need for additional studies to assess the potential for increased cardiovascular events with Merck’s Vioxx was cited in FDA’s original review, according to NDA review documents for the COX-2 inhibitor.